Abstract
AbstractPost-acute health care costs following SARS-CoV-2 infection are not known. Beginning 56 days following SARS-CoV-2 polymerase chain reaction (PCR) testing, we compared person-specific total and component health care costs across their distribution for the following year (test-positive versus test-negative, matched people; January 1, 2020-March 31, 2021). For 531,182 individuals, mean person-specific total health care costs were $513.83 (95% CI $387.37-$638.40) higher for test-positive females and $459.10 (95% CI $304.60-$615.32) higher for test-positive males, or >10% increase in mean per-capita costs, driven by hospitalization, long-term care, and complex continuing care costs. At the 99thpercentile of each subgroup, person-specific health care costs were $12,533.00 (95% CI $9,008.50-$16,473.00) higher for test-positive females and $14,604.00 (95% CI $9,565.50-$19,506.50) for test-positive males, driven by hospitalization, specialist (males), and homecare costs (females). Cancer costs were lower. Six-month and 1-year costs differences were similar. These findings can inform planning for post-acute SARS-CoV-2 health care costs.
Publisher
Cold Spring Harbor Laboratory
Reference84 articles.
1. StatCan. Between April and August 2022, 98% of Canadians had antibodies against COVID-19 and 54% had antibodies from a previous infection. https://www150.statcan.gc.ca/n1/daily-quotidien/230327/dq230327b-eng.htm?fbclid=IwAR0jVe20IawIj2JDuAcDFkS30fjffEo04UHM9F281bVJxvBm_Sm0z7C0qvQ Last accessed March 20, 2023.
2. COVID-19 Immunity Task Force. Seroprevalence against SARS-CoV-2 due to infection in Canada: Results from the Government of Canada’s COVID-19 Immunity Task Force and other partners’ funded studies through to May 31, 2022. https://www.covid19immunitytaskforce.ca/wp-content/uploads/2022/07/CITF_Bespoke-report_Omicron-tsunami_2022_FINAL_ENG.pdf Last accessed August 29, 2022.
3. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int. Last accessed March 29, 2023.
4. Initial health care costs for COVID-19 in British Columbia and Ontario, Canada: an interprovincial population-based cohort study
5. Xie Y , Xu E , Bowe B , Al-Aly Z . Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022.